2016


To access this material please log in or register

Register Authorize
2016/№5

Treatment of chronic heart failure with preserved left ventricular ejection fraction: comparing two types of pulse-slowing therapy

Kanorskiy S. G., Borisenko Yu. V.
FSBEI HE "Kuban State Medical University" of the Ministry of health care of Russia, Sedina str., 4, Krasnodar 350063, Russia

Keywords: heart failure, preserved ejection fraction, ivabradine, bisoprolol, left ventricle, diastolic dysfunction

DOI: 10.18087/rhfj.2016.5.2283

Background. Treatment of patients with CHF and preserved LV EF remains largely empiric since none of the therapies has improved prognosis of the patients. Aim. To compare efficacies of bisoprolol and ivabradine in the treatment of CHF with preserved LV EF. Materials and methods. In this prospective, randomized study, 126 patients with CHF and LV EF ≥50 % associated with AH and IHD received a fixed-dose perindopril/amlodipine combination supplemented with bisoprolol (n=62) or ivabradine (n=64). Clinical status, exercise tolerance, quality of life, blood NT-proBNP, and EchoCG parameters were evaluated at background and after 12 months of the treatment. Results. As distinct from bisoprolol, ivabradine considerably increased exercise tolerance and quality of life, decreased levels of NT-proBNP, and improved EchoCG indexes of LV active relaxation and compliance. Conclusion. Ivabradine was superior to bisoprolol in treatment of patients with CHF and preserved LV EF associated with AH and IHD.
  1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37 (27):2129–200.
  2. Reddy YN, Borlaug BA. Heart Failure With Preserved Ejection Fraction. Curr Probl Cardiol. 2016 Apr;41 (4):145–88.
  3. Loop MS, Van Dyke MK, Chen L, Brown TM, Durant RW, Safford MM, Levitan EB. Comparison of length of stay, 30‑day mortality, and 30‑day readmission rates in medicare patients with heart failure and with reduced versus preserved ejection fraction. Am J Cardiol. 2016 Jul 1;118 (1):79–85.
  4. Kapłon-Cieślicka A, Tymińska A, Peller M, Balsam P, Ozieranski K, Galas M et al. Diagnosis, clinical course, and 1‑year outcome in patients hospitalized for heart failure with preserved ejection fraction (from the polish cohort of the European Society of Cardiology Heart Failure Long-Term Registry). Am J Cardiol. 2016 Aug 15;118 (4):535–42.
  5. Goyal P, Almarzooq ZI, Horn EM, Karas MG, Sobol I, Swaminathan RV et al. Characteristics of hospitalizations for heart failure with preserved ejection fraction. Am J Med. 2016 Jun;129 (6):635.e15–26.
  6. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016 Jul 5;134 (1):73–90.
  7. Gheorghiade M, Larson CJ, Shah SJ, Greene SJ, Cleland JG, Colucci WS et al. Developing new treatments for heart failure: focus on the heart. Circ Heart Fail. 2016 May;9 (5):pii:e002727.
  8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology / American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016 Sep 27;68(13):1476–88.
  9. Borer JS, Tavazzi L. Update on ivabradine for heart failure. Trends Cardiovasc Med. 2016 Jul;26 (5):444–9.
  10. Henri C, O'Meara E, De Denus S, Elzir L, Tardif JC. Ivabradine for the treatment of chronic heart failure. Expert Rev Cardiovasc Ther. 2016;14 (5):553–61.
  11. Pereira-Barretto AC. Addressing major unmet needs in patients with systolic heart failure: the role of ivabradine. Am J Cardiovasc Drugs. 2016 Apr;16 (2):93–101.
  12. Psotka MA, Teerlink JR. Ivabradine: role in the chronic heart failure armamentarium. Circulation. 2016 May 24;133 (21):2066–75.
  13. Petite SE, Bishop BM, Mauro VF. Role of the funny current inhibitor ivabradine in cardiac pharmacotherapy: a systematic review. Am J Ther. 2016 Feb 23. [Epub ahead of print].
  14. Канорский С. Г. Частота сердечных сокращений и кардиопротекция: новые данные и перспективы. Кардиология. 2015;55(8):55–61 [Kanorskij S. G. Chastota serdechny`x sokrashhenij i kardioprotekcziya: novy`e danny`e i perspektivy`. Kardiologiya. 2015;55 (8):55–61].
  15. Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013 Oct 8;62(15):1330–8.
  16. Pal N, Sivaswamy N, Mahmod M, Yavari A, Rudd A, Singh S et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation. 2015 Nov 3;132(18):1719–25.
  17. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007 Oct;28 (20):2539–50.
  18. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009 Feb;22 (2):107–33.
  19. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 Dec;18(12):1440–63.
  20. Dalos D, Mascherbauer J, Zotter-Tufaro C, Duca F, Kammerlander AA, Aschauer S, Bonderman D. Functional status, pulmonary artery pressure, and clinical outcomes in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2016 Jul 12;68 (2):189–99.
  21. van Heerebeek L, Paulus WJ. Understanding heart failure with preserved ejection fraction: where are we today? Neth Heart J. 2016 Apr;24 (4):227–36.
  22. Franssen C, González Miqueo A. The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Neth Heart J. 2016 Apr;24 (4):259–67.
  23. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10;370 (15):1383–92.
  24. Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015 Oct 7;36 (38):2565–73.
  25. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015 Dec 10;373(24):2314–24.
  26. Teo LY, Chan LL, Lam CS. Heart failure with preserved ejection fraction in hypertension. Curr Opin Cardiol. 2016 Jul;31 (4):410–6.
  27. Srivaratharajah K, Coutinho T, deKemp R, Liu P, Haddad H, Stadnick E et al. Reduced myocardial flow in heart failure patients with preserved ejection fraction. Circ Heart Fail. 2016 Jul;9 (7):pii:e002562.
  28. Gloekler S, Traupe T, Stoller M, Schild D, Steck H, Khattab A et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart. 2014 Jan;100 (2):160–6.
  29. De Marchi SF, Gloekler S, Rimoldi SF, Steck H, Seller C. Regulation of myocardial perfusion at high perfusion pressure during external counterpulsation. Eur Heart J. 2009;30 (Suppl): 797 (4757).
  30. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Deswal A, Anand IS et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circ Heart Fail. 2015 Nov;8(6):1052–8.
  31. Aung SM, Güler A, Güler Y, Huraibat A, Karabay CY, Akdemir I. Left atrial strain in heart failure with preserved ejection fraction. Herz. 2016 Jun 28. [Epub ahead of print].
  32. Santos AB, Roca GQ, Claggett B, Sweitzer NK, Ahah SJ, Anand IS et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail. 2016 Apr;9(4):e002763.
  33. Ozturk S, Öztürk S, Erdem FH, Erdem A, Ayhan S, Donmez I, Yazici M. The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure. J Interv Card Electrophysiol. 2016 Sep;46 (3):253–8.
  34. Kitai T, Tang WH. Pathophysiologic insights into heart rate reduction in heart failure: implications in the use of beta-blockers and ivabradine. Curr Treat Options Cardiovasc Med. 2016 Feb;18 (2):13.
  35. Barillà F, Pannarale G, Torromeo C, Paravati V, Acconcia MC, Tanzilli G et al. Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective study. Clin Drug Investig. 2016 Oct;36(10):849–56.
  36. Kansal AR, Cowie MR, Kielhorn A, Krotneva S, Tafazzoli A, Zheng Y, Yurgin N. Cost-effectiveness of ivabradine for heart failure in the United States. J Am Heart Assoc. 2016 May 6;5(5):pii:e003221.
  37. Komajda M, Tavazzi L, Swedberg K, Bohm M, Borer JS, Moyne A, Ford I. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. Eur J Heart Fail. 2016Sep;18 (9):1182–9.
  38. Heusch G, Kleinbongard P. Ivabradine: cardioprotection by and beyond heart rate reduction. Drugs. 2016 May;76 (7):733–40.
Kanorskiy S.G., Borisenko Yu.V. Treatment of chronic heart failure with preserved left ventricular ejection fraction: comparing two types of pulse-slowing therapy. Russian Heart Failure Journal. 2016;17 (5):306–311

To access this material please log in or register

Register Authorize
Ru En